NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today that it has granted a stock option to purchase 20,000 shares
of common stock to one new employee. The stock option was granted
pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan and
granted as an inducement material to the new employee entering into
employment with Seelos in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock option has an exercise price equal to $1.06, the closing price per share of Seelos'
common stock, as reported by Nasdaq, on July
1, 2020, the date of grant. The option is a non-qualified
stock option and 1/4th of the shares vest on the one-year
anniversary of the new employee's commencement of employment and an
additional 1/48th of the shares vest monthly thereafter over the
next three years, in each case provided that the new employee
remains continuously employed by Seelos through the applicable
vesting date, inclusive.
Seelos is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Seelos Therapeutics
Seelos Therapeutics, Inc. is
a clinical-stage biopharmaceutical company focused on the
development and advancement of novel therapeutics to address unmet
medical needs for the benefit of patients with central nervous
system (CNS) disorders and other rare diseases. The Company's
robust portfolio includes several late-stage clinical assets
targeting indications including Acute Suicidal Ideation and
Behavior (ASIB) in Major Depressive Disorder (MDD) or
Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome,
Parkinson's Disease, other psychiatric and movement disorders plus
orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward-looking Statements
This press release contains
forward-looking statements subject to risks and uncertainties that
could cause actual results to differ materially from those
projected. Forward-looking statements include statements about the
employees and equity plans. Risks and uncertainties include risks
associated with the Company's employees and equity plans, and
additional risks set forth in the Company's filings with the
Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl.
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original
content:http://www.prnewswire.com/news-releases/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-301095061.html
SOURCE Seelos Therapeutics, Inc.